Inflammatory Phenotypes In Severe Pneumonia: Clinical Evidence To Mouse Models For Precision Therapeutics.

Summary

Latent class analysis identified hyperinflammatory and hypoinflammatory phenotypes among 548 critically ill patients with pulmonary sepsis; the hyperinflammatory phenotype was associated with greater lung injury and mortality. A pneumococcal pneumonia mouse model reproduced divergent inflammatory trajectories despite uniform pathogen exposure, and dexamethasone or IL-6 receptor blockade benefited only the more inflamed phenotype. This provides a clinically anchored framework for phenotype-targeted therapy in severe pneumonia.

Key Findings

• Among 548 patients with pulmonary sepsis, two inflammatory phenotypes were identified; the hyperinflammatory phenotype had greater lung injury and mortality.
• A pneumococcal pneumonia mouse model reproduced distinct inflammatory trajectories despite uniform pathogen exposure and baseline conditions.
• Dexamethasone and interleukin-6 receptor blockade produced therapeutic benefit exclusively in the more inflamed mouse phenotype.

Clinical Implications

Routine biomarker-based phenotyping may eventually identify pneumonia patients more likely to benefit from immunomodulatory therapy. The findings support prospective trials that stratify patients by inflammatory phenotype rather than applying uniform anti-inflammatory treatment.

Limitations

• The clinical phenotype classification is observational and does not establish that the identified subgroups are caused by a single biological mechanism.
• The mouse model cannot reproduce the full heterogeneity, comorbidity burden, and treatment context of human severe pneumonia.

Future Directions

Prospective biomarker-stratified clinical trials should test whether phenotype-guided corticosteroid or interleukin-6 pathway therapy improves outcomes and should evaluate the stability of phenotypes over time.